Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	brush border	ESPN FLNB MYH10 SLC34A2 MYO1B SLC23A1 SLC6A14 ALPI	3.24e-05	152	168	8	GO:0005903
GeneOntologyCellularComponent	apical part of cell	ERBB2 NAALADL1 USP9X CEACAM7 ANO1 SLC34A2 MYO1B CEACAM1 SHROOM4 DCHS1 PRKG2 RAPGEF2 CDH1 SLC23A1 SLC6A14	9.05e-05	592	168	15	GO:0045177
GeneOntologyCellularComponent	endoplasmic reticulum exit site	TFG SEC24B SEC16A SEC23B	3.55e-04	42	168	4	GO:0070971
GeneOntologyCellularComponent	cluster of actin-based cell projections	ESPN FLNB MYH10 SLC34A2 MYO1B SLC23A1 SLC6A14 ALPI	4.56e-04	223	168	8	GO:0098862
GeneOntologyCellularComponent	microvillus	ESPN ERBB2 SLC34A2 MYO1B CEACAM1 CDH1	4.82e-04	123	168	6	GO:0005902
HumanPheno	Tracheomalacia	FLNB TRIM2 USP9X DCHS1 CHD6 MYRF	1.17e-05	49	55	6	HP:0002779
Domain	GTPase_binding	ERRFI1 TNK2	7.85e-05	2	166	2	PF09027
Domain	Inhibitor_Mig-6	ERRFI1 TNK2	7.85e-05	2	166	2	PF11555
Domain	Fam133	FAM133A FAM133B	7.85e-05	2	166	2	IPR026766
Domain	Mig-6	ERRFI1 TNK2	7.85e-05	2	166	2	IPR021619
Domain	Cdc42_binding_dom-like	ERRFI1 TNK2	7.85e-05	2	166	2	IPR015116
Domain	SUZ	ARPP21 R3HDM1	2.34e-04	3	166	2	PF12752
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	ESPN NCOA2 FLNB MBTPS1 ERBB2 MYH10 MINK1 BARD1 TNRC6B CHD9 FNBP1L ME2 FAF1 PDXK PACS1 ZBTB46 PPP2R3A ATXN1 NUP210 ANKRD11 TNK2 CHD6 CAMTA1 RAPGEF2 USP15 EP300 MAN1B1 KDM4B	8.20e-10	1489	169	28	28611215
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	MBTPS1 MYH10 RBM10 SPEG TNRC6B PUM2 MED13L SEC16A CHD6 CAMTA1 MAPKBP1 R3HDM1 USP15 RUBCN	1.43e-08	407	169	14	12693553
Pubmed	Construction of a multi-functional cDNA library specific for mouse pancreatic islets and its application to microarray.	NCOA2 KCTD12 FLNB MBTPS1 ADAMTS1 KLC4 ERRFI1 RAPGEF2 CDH1 RUBCN SEC23B KDM4B	3.08e-07	371	169	12	15747579
Pubmed	Human transcription factor protein interaction networks.	NCOA2 MYH10 USP9X RBM10 ETV4 TNRC6B PUM2 DIDO1 MYO1B PROSER1 CUL7 PRDM2 EIF4ENIF1 ZFHX4 ATXN1 G3BP2 SEC24B SEC16A CHD6 PAX9 R3HDM1 EP300 SEC23B	4.92e-07	1429	169	23	35140242
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	NCOA2 GAPVD1 USP9X RBM10 TNRC6B DIDO1 GTF3C5 SEC24B SEC16A PKN2 PC USP15 EP300 TP53BP2	5.54e-07	549	169	14	38280479
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	NCOA2 TNRC6B PUM2 PROSER1 CCDC120 R3HDM1 PLK4 EP300	8.52e-07	152	169	8	38360978
Pubmed	mTORC1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis.	FLNB MYH10 RBM10 PUM2 MYO1B G3BP2 SEC24B SEC16A R3HDM1 SEC23B	1.04e-06	274	169	10	34244482
Pubmed	Regulation of aggrecanases from the ADAMTS family and aggrecan neoepitope formation during in vitro chondrogenesis of human mesenchymal stem cells.	ADAMTS1 ADAMTS5 ADAMTS16	1.12e-06	5	169	3	22562232
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	ERBB2 GAPVD1 MINK1 KLC4 CEP350 ATXN1 SEC24B SEC16A ANKRD11 SIK2 RAPGEF2 R3HDM1 PC PLK4 PRRC1 SEC23B TP53BP2	1.15e-06	861	169	17	36931259
Pubmed	Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.	TNRC6B PUM2 MED13L SEC16A SIK2 CHD6 CAMTA1 USP15 KDM4B	1.72e-06	225	169	9	12168954
Pubmed	A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration.	RBM10 TNRC6B KLC4 BEND2 CEP350 PPP2R3A EIF4ENIF1 ATXN1 ARNT2 CHD6 MAPKBP1 R3HDM1 TP53BP2 KPNA3	1.84e-06	608	169	14	16713569
Pubmed	A new role for the architecture of microvillar actin bundles in apical retention of membrane proteins.	ESPN FLNB MYH10 MYO1B ALPI	2.67e-06	45	169	5	22114352
Pubmed	An antibody-based proximity labeling map reveals mechanisms of SARS-CoV-2 inhibition of antiviral immunity.	GAPVD1 NEBL TNRC6B PUM2 TFG GTF3C5 CEP350 EIF4ENIF1 ARNT2 SEC16A DDX20 CHD6 R3HDM1 USP15 PRRC1	3.29e-06	733	169	15	34672954
Pubmed	Co-adaptor driven assembly of a CUL3 E3 ligase complex.	USP9X SEC24B SEC16A SEC23B	3.68e-06	22	169	4	35120648
Pubmed	Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.	ERRFI1 TNK2 ALK	3.89e-06	7	169	3	19815557
Pubmed	E-cadherin interactome complexity and robustness resolved by quantitative proteomics.	FLNB ERBB2 GAPVD1 NEBL MINK1 MYO1B FNBP1L SEC24B CCDC120 PKN2 USP15 CDH1 TP53BP2	4.38e-06	565	169	13	25468996
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	NCOA2 FLNB ADAMTS1 USP9X USP25 CHD9 FBXO11 MED13L PRDM4 FAF1 CEP350 WDR3 PIAS3 KDM4A CHD6 RAPGEF2 R3HDM1 PC EP300 KPNA3	4.81e-06	1285	169	20	35914814
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	NCOA2 KCTD12 MYH10 USP9X MINK1 WDR81 TNRC6B DIDO1 GRM4 G3BP2 CASKIN1 SEC16A DCHS1 ARC RAPGEF2 BSN TP53BP2	5.14e-06	963	169	17	28671696
Pubmed	Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu.	NCOA2 ERBB2 EP300	6.20e-06	8	169	3	14747462
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	GAPVD1 MINK1 TNRC6B TFG CEP350 WDR3 PPP2R3A SEC24B SEC16A ADAMTS16 RAPGEF2 PC SDK1 PRRC1 SEC23B	6.62e-06	777	169	15	35844135
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	FLNB GAPVD1 TNRC6B GTF3C5 PRDM2 EIF4ENIF1 ZFHX4 SEC16A CHD6 PC TP53BP2	7.01e-06	418	169	11	34709266
Pubmed	Functional proteomics mapping of a human signaling pathway.	FLNB MYH10 USP25 PRDM4 FAF1 NEDD9 ZFYVE9 PIAS3 HTATSF1 CHD6 SDK1 RUBCN TP53BP2	7.09e-06	591	169	13	15231748
Pubmed	Proteomic Analysis of the EWS-Fli-1 Interactome Reveals the Role of the Lysosome in EWS-Fli-1 Turnover.	KCTD12 CECR2 ANO1 PROSER1 TFG EIF4ENIF1 NUP210 HTATSF1 PAX9 R3HDM1 EP300	8.19e-06	425	169	11	24999758
Pubmed	New nomenclature for chromatin-modifying enzymes.	NCOA2 PRDM2 KDM4A EP300 KDM4B	8.71e-06	57	169	5	18022353
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	PRDM4 NEDD9 EIF4ENIF1 PIAS3 HTATSF1 TNK2 CAMTA1 BSN PRRC1 TP53BP2 KPNA3	9.14e-06	430	169	11	35044719
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	NCOA2 ZSCAN5DP RBM10 ETV4 DIDO1 PRDM4 ZNF496 GTF3C5 CERS5 ZBTB46 PIAS3 ATXN1 ARNT2 KDM4A KDM4B	1.05e-05	808	169	15	20412781
Pubmed	Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro.	DIDO1 CHD9 ARNT2 SEC16A IGSF1 RAPGEF2	1.23e-05	104	169	6	9205841
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	KCTD12 GAPVD1 MYH10 NEBL RBM10 TNRC6B PUM2 DIDO1 MYO1B ME2 SEC24B SEC16A HTATSF1 PKN2 PC TP53BP2	1.43e-05	934	169	16	33916271
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	MYH10 USP9X MINK1 MYO1B CUL7 CEP350 PACS1 PPP2R3A ZFYVE9 C1orf226 NUP210 SEC24B SEC16A PC PLK4 TP53BP2 KPNA3	1.55e-05	1049	169	17	27880917
Pubmed	SNX27-driven membrane localisation of OTULIN antagonises linear ubiquitination and NF-κB signalling activation.	RBM10 USP25 TNRC6B FNBP1L GTF3C5 SEC24B HTATSF1 RAPGEF2 USP15 SEC23B	1.77e-05	378	169	10	34315543
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	FLNB GAPVD1 MYH10 USP9X DIDO1 MYO1B CUL7 ME2 WDR3 NUP210 SEC16A DDX20 SEC23B	2.03e-05	653	169	13	22586326
Pubmed	PIAS3 (protein inhibitor of activated STAT-3) modulates the transcriptional activation mediated by the nuclear receptor coactivator TIF2.	NCOA2 PIAS3	2.35e-05	2	169	2	12208521
Pubmed	Combined high NEDD9 expression and E-cadherin loss correlate with poor clinical outcome in gastric cancer.	NEDD9 CDH1	2.35e-05	2	169	2	36203318
Pubmed	USP25 inhibits DNA damage by stabilizing BARD1 protein in a house dust mite-induced asthmatic model in vitro and in vivo.	USP25 BARD1	2.35e-05	2	169	2	35143098
Pubmed	Expression of HER2/neu in gastric adenocarcinoma and its correlation with serum HER2/neu level and E-cadherin expression.	ERBB2 CDH1	2.35e-05	2	169	2	35074963
Pubmed	Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain.	ERBB2 ERRFI1	2.35e-05	2	169	2	11003669
Pubmed	Pathogenic variants in EP300 and ANKRD11 in patients with phenotypes overlapping Cornelia de Lange syndrome.	ANKRD11 EP300	2.35e-05	2	169	2	32476269
Pubmed	Loss of E-cadherin expression is not a prerequisite for c-erbB2-induced epithelial-mesenchymal transition.	ERBB2 CDH1	2.35e-05	2	169	2	24807161
Pubmed	Reader domain specificity and lysine demethylase-4 family function.	KDM4A KDM4B	2.35e-05	2	169	2	27841353
Pubmed	Loss of MIG-6 results in endometrial progesterone resistance via ERBB2.	ERBB2 ERRFI1	2.35e-05	2	169	2	35232969
Pubmed	Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells.	ETV4 EP300	2.35e-05	2	169	2	14976201
Pubmed	Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype.	ERBB2 CDH1	2.35e-05	2	169	2	29295527
Pubmed	Human enhancer of filamentation 1-induced colorectal cancer cell migration: Role of serine phosphorylation and interaction with the breast cancer anti-estrogen resistance 3 protein.	NEDD9 BCAR3	2.35e-05	2	169	2	25817040
Pubmed	Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells.	ERBB2 PRKG2	2.35e-05	2	169	2	26676300
Pubmed	TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations.	TFG ALK	2.35e-05	2	169	2	10556217
Pubmed	Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer.	ERBB2 ETV4	2.35e-05	2	169	2	16752078
Pubmed	Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.	TFG ALK	2.35e-05	2	169	2	11943732
Pubmed	Structural insights into the association between BCAR3 and Cas family members, an atypical complex implicated in anti-oestrogen resistance.	NEDD9 BCAR3	2.35e-05	2	169	2	19103205
Pubmed	Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.	ERBB2 CDH1	2.35e-05	2	169	2	23575477
Pubmed	Investigation roles of Adamts1 and Adamts5 in scleral fibroblasts under hypoxia and mice with form-deprived myopia.	ADAMTS1 ADAMTS5	2.35e-05	2	169	2	39122105
Pubmed	4E-T-bound mRNAs are stored in a silenced and deadenylated form.	TNRC6B EIF4ENIF1	2.35e-05	2	169	2	32354837
Pubmed	ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.	ERBB2 CDH1	2.35e-05	2	169	2	27811364
Pubmed	Inhibition of p300 histone acetyltransferase activity in palate mesenchyme cells attenuates Wnt signaling via aberrant E-cadherin expression.	CDH1 EP300	2.35e-05	2	169	2	26921506
Pubmed	Cloning and expression analysis of a novel mouse gene with sequence similarity to the Drosophila fat facets gene.	USP9X FAF1	2.35e-05	2	169	2	9178254
Pubmed	ADAMTS1 and ADAMTS5 metalloproteases produced by Sertoli cells: a potential diagnostic marker in azoospermia.	ADAMTS1 ADAMTS5	2.35e-05	2	169	2	29737873
Pubmed	Transcriptional repression of HER2 by ANO1 Cl- channel inhibition in human breast cancer cells with resistance to trastuzumab.	ERBB2 ANO1	2.35e-05	2	169	2	27838298
Pubmed	Human variants in the neuronal basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) transcription factor complex NPAS4/ARNT2 disrupt function.	ARNT2 NPAS4	2.35e-05	2	169	2	24465693
Pubmed	The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis.	ERBB2 ETV4	2.35e-05	2	169	2	11719215
Pubmed	Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.	ERBB2 CDH1	2.35e-05	2	169	2	22237715
Pubmed	Role of ADAMTS1 and ADAMTS5 in male infertility.	ADAMTS1 ADAMTS5	2.35e-05	2	169	2	26888488
Pubmed	Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.	ERBB2 ERRFI1	2.35e-05	2	169	2	15856022
Pubmed	Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.	ERBB2 CDH1	2.35e-05	2	169	2	28325747
Pubmed	The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a pluripotency sub-network that includes DPPA4, a regulator of embryogenesis.	USP9X CECR2 DIDO1 FBXO11 PPP2R3A USP42 PRCP DDX20 USP15 PRRC1	2.62e-05	396	169	10	26687479
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	NCOA2 CECR2 PRDM2 WDR3 ZFHX4 SEC16A DDX20 EP300 KDM4B KPNA3	2.74e-05	398	169	10	35016035
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	MYH10 FAM133A PCDHAC2 TNRC6B DIDO1 FBXO11 MYO1B TFG GTF3C5 TSFM CEP350 WDR3 G3BP2 SEC16A DDX20 AURKAIP1 PC ALK KPNA3	4.15e-05	1371	169	19	36244648
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	GAPVD1 RBM10 TNRC6B EIF4ENIF1 SEC24B SEC16A R3HDM1 TP53BP2	4.70e-05	263	169	8	34702444
Pubmed	Non-muscle myosin II deletion in the developing kidney causes ureter-bladder misconnection and apical extrusion of the nephric duct lineage epithelia.	MYH10 ETV4 CDH1	4.91e-05	15	169	3	28478097
Pubmed	Interaction network of human early embryonic transcription factors.	NCOA2 PROSER1 ME2 PRDM2 ZFHX4 ATXN1 SEC16A CDH1 EP300	5.95e-05	351	169	9	38297188
Pubmed	ADAMTS18 Deficiency Affects Neuronal Morphogenesis and Reduces the Levels of Depression-like Behaviors in Mice.	ADAMTS1 ADAMTS5 ADAMTS16	6.03e-05	16	169	3	30579834
Pubmed	A protein interaction landscape of breast cancer.	ERBB2 GAPVD1 MYH10 FAM133A USP9X BARD1 MYO1B CUL7 RIN1 TSPYL5 CDH1 KPNA3	6.88e-05	634	169	12	34591612
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	KCTD12 FLNB GAPVD1 MYH10 USP9X AZGP1 MYO1B TFG ME2 GTF3C5 PDXK TSFM PRDM2 WDR3 G3BP2 NUP210 DDX20 BSN PC	6.94e-05	1425	169	19	30948266
Pubmed	HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.	ERBB2 ALK	7.02e-05	3	169	2	28656214
Pubmed	KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.	KDM4A KDM4B	7.02e-05	3	169	2	26397136
Pubmed	Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17.	ADAMTS1 ADAMTS5	7.02e-05	3	169	2	23859810
Pubmed	Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex.	ERBB2 ANKRD11	7.02e-05	3	169	2	24678732
Pubmed	Comparison of ADAMTS-1, -4 and -5 expression in culprit plaques between acute myocardial infarction and stable angina.	ADAMTS1 ADAMTS5	7.02e-05	3	169	2	21345877
Pubmed	Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.	TNK2 EP300	7.02e-05	3	169	2	15964811
Pubmed	NANOS1 and PUMILIO2 bind microRNA biogenesis factor GEMIN3, within chromatoid body in human germ cells.	PUM2 DDX20	7.02e-05	3	169	2	21800163
Pubmed	Snail acetylation by histone acetyltransferase p300 in lung cancer.	CDH1 EP300	7.02e-05	3	169	2	28296173
Pubmed	HER2 activation results in β-catenin-dependent changes in pulmonary epithelial permeability.	ERBB2 CDH1	7.02e-05	3	169	2	25326580
Pubmed	Long-range chromosomal mapping of the carcinoembryonic antigen (CEA) gene family cluster.	CEACAM7 CEACAM1	7.02e-05	3	169	2	1572649
Pubmed	Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).	NEDD9 CDH1	7.02e-05	3	169	2	29924959
Pubmed	Determinants of versican-V1 proteoglycan processing by the metalloproteinase ADAMTS5.	ADAMTS1 ADAMTS5	7.02e-05	3	169	2	25122765
Pubmed	Collective Wisdom: Lobular Carcinoma of the Breast.	ERBB2 CDH1	7.02e-05	3	169	2	27249682
Pubmed	Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300.	CTF1 EP300	7.02e-05	3	169	2	11030335
Pubmed	Comparative integromics on JMJD2A, JMJD2B and JMJD2C: preferential expression of JMJD2C in undifferentiated ES cells.	KDM4A KDM4B	7.02e-05	3	169	2	17611647
Pubmed	HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells.	ERBB2 CDH1	7.02e-05	3	169	2	23542467
Pubmed	Regulated expression of ADAMTS family members in follicles and cumulus oocyte complexes: evidence for specific and redundant patterns during ovulation.	ADAMTS1 ADAMTS5	7.02e-05	3	169	2	15659705
Pubmed	Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.	NEDD9 CDH1	7.02e-05	3	169	2	23086683
Pubmed	Ataxin-1 occupies the promoter region of E-cadherin in vivo and activates CtBP2-repressed promoter.	ATXN1 CDH1	7.02e-05	3	169	2	21315774
Pubmed	Transcriptional programming mediated by the histone demethylase KDM5C regulates dendritic cell population heterogeneity and function.	IFNAR1 ZBTB46	7.02e-05	3	169	2	39052479
Pubmed	A genome-wide association study for malignant mesothelioma risk.	CRTAM SDK1	7.02e-05	3	169	2	23827383
Pubmed	Conserved linkage of soluble aconitase and galactose-1-phosphate uridyl transferase in mouse and man: assignment of these genes to mouse chromosome 4.	GALT TYRP1	7.02e-05	3	169	2	6297853
Pubmed	Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development.	KDM4A KDM4B	7.02e-05	3	169	2	27266524
Pubmed	The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin.	USP9X CDH1	7.02e-05	3	169	2	14742711
Pubmed	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.	CDH1 TP53BP2	7.02e-05	3	169	2	32060147
Pubmed	Structures of NPAS4-ARNT and NPAS4-ARNT2 heterodimers reveal new dimerization modalities in the bHLH-PAS transcription factor family.	ARNT2 NPAS4	7.02e-05	3	169	2	36343253
Pubmed	The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation.	ERBB2 CDH1	7.02e-05	3	169	2	18434311
Pubmed	The histone demethylase JMJD2C is stage-specifically expressed in preimplantation mouse embryos and is required for embryonic development.	KDM4A KDM4B	7.02e-05	3	169	2	19696013
Pubmed	SIK2 regulates fasting-induced PPARα activity and ketogenesis through p300.	SIK2 EP300	7.02e-05	3	169	2	26983400
Interaction	R3HDM2 interactions	ARPP21 TNRC6B PUM2 TFG EIF4ENIF1 ATXN1 G3BP2 SEC24B SEC16A R3HDM1	9.78e-08	129	163	10	int:R3HDM2
Interaction	ZYX interactions	NEBL USP9X AZGP1 TNRC6B MYO1B CEP350 NEDD9 ATXN1 SEC16A CDH1 EP300 SEC23B TP53BP2	2.90e-06	329	163	13	int:ZYX
Interaction	YWHAG interactions	GAPVD1 MYH10 NDE1 SPEG MINK1 CUL7 KLC4 FAF1 CEP350 PACS1 RIN1 ATXN1 SEC24B ERRFI1 SEC16A ANKRD11 SIK2 TNK2 PKN2 RAPGEF2 R3HDM1 PLK4 RUBCN PRRC1 SEC23B TP53BP2	8.10e-06	1248	163	26	int:YWHAG
Interaction	SEC23B interactions	ERBB2 TNRC6B RIN1 SEC24B SEC16A ALK EP300 PRRC1 SEC23B MAN1B1	1.36e-05	222	163	10	int:SEC23B
Interaction	SAR1A interactions	CXCL16 CUL7 TFG ATXN1 SYNGR1 SEC24B SEC16A PC EP300 PRRC1 SEC23B MAN1B1	1.39e-05	325	163	12	int:SAR1A
Interaction	FGFR1 interactions	ERBB2 MINK1 FNBP1L KLC4 TFG IFNAR1 PACS1 RIN1 ZFYVE9 C1orf226 SEC24B TNK2 PKN2 CDH1 ALK SEC23B TP53BP2	1.51e-05	632	163	17	int:FGFR1
Interaction	KLHL12 interactions	USP9X USP25 RIN1 ATXN1 SEC24B SEC16A SEC23B	2.19e-05	104	163	7	int:KLHL12
Interaction	YWHAH interactions	NCOA2 GAPVD1 NDE1 SPEG MINK1 KLC4 FAF1 CEP350 PACS1 RIN1 ATXN1 SEC24B ERRFI1 SEC16A ANKRD11 SIK2 RAPGEF2 R3HDM1 PLK4 RUBCN PRRC1 SEC23B TP53BP2	2.79e-05	1102	163	23	int:YWHAH
Interaction	GOLGA2 interactions	NCOA2 MYH10 NEBL NDE1 SYT6 BARD1 MYO1B RIN1 ZNF648 SEC24B ARNT2 SEC16A ANKRD11 CCDC120 DDX20 USP15 CDH1 EP300	2.83e-05	733	163	18	int:GOLGA2
Interaction	EYA4 interactions	NCOA2 KCTD12 TNRC6B PUM2 PROSER1 SEC24B CCDC120 R3HDM1 PLK4 EP300	2.97e-05	243	163	10	int:EYA4
Interaction	WWTR1 interactions	NCOA2 GAPVD1 RBM10 TNRC6B DIDO1 CERS5 SEC24B ARNT2 SEC16A PKN2 USP15 EP300 TP53BP2	4.07e-05	422	163	13	int:WWTR1
Interaction	ANXA1 interactions	MYH10 USP9X USP25 CUL7 TFG FAF1 PIAS3 G3BP2 PKN2 CDH1 TP53BP2	4.10e-05	306	163	11	int:ANXA1
Interaction	YWHAZ interactions	ERBB2 GAPVD1 MYH10 NDE1 SPEG AZGP1 MINK1 BARD1 CUL7 KLC4 TFG FAF1 PACS1 RIN1 ATXN1 ERRFI1 SIK2 TNK2 RAPGEF2 R3HDM1 CDH1 PLK4 RUBCN EP300 TP53BP2	5.92e-05	1319	163	25	int:YWHAZ
Interaction	USO1 interactions	NCOA2 SYT6 DNAH2 ATXN1 SEC16A DDX20 CDH1 ALK EP300	6.55e-05	215	163	9	int:USO1
Interaction	SEC24A interactions	ERBB2 TNRC6B TFG SEC24B SEC16A ALK EP300 PRRC1 SEC23B	8.98e-05	224	163	9	int:SEC24A
Interaction	PXN interactions	TNRC6B ITGA9 CEACAM1 CEP350 NEDD9 SEC16A DDX20 BCAR3 CDH1 ALK SEC23B	8.98e-05	334	163	11	int:PXN
Interaction	GAPVD1 interactions	GAPVD1 MYH10 FBXO11 FAF1 ATXN1 USP15 CDH1 EP300	1.11e-04	180	163	8	int:GAPVD1
Cytoband	Xq25	TEX13C DCAF12L2 DCAF12L1 IGSF1	1.61e-05	41	169	4	Xq25
Cytoband	5p15	TENT4A ADAMTS16	2.79e-04	7	169	2	5p15
GeneFamily	ADAM metallopeptidases with thrombospondin type 1 motif	ADAMTS1 ADAMTS5 ADAMTS16	1.93e-04	19	109	3	50
GeneFamily	Ubiquitin specific peptidases	USP9X USP25 USP42 USP15	3.61e-04	56	109	4	366
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN	FLNB GAPVD1 TRIM2 USP9X BARD1 PUM2 CHD9 MYO1B FNBP1L MED13L CEP350 PPP2R3A ZFYVE9 SEC24B PKN2 BCAR3 RAPGEF2 R3HDM1 TP53BP2 KPNA3	2.40e-11	466	168	20	M13522
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	NCOA2 FLNB GAPVD1 TRIM2 USP9X BARD1 PUM2 CHD9 MYO1B FNBP1L MED13L ME2 CEP350 PPP2R3A ZFYVE9 ATXN1 SEC24B ARNT2 PKN2 BCAR3 RAPGEF2 R3HDM1 USP15 TP53BP2 KPNA3	2.54e-10	856	168	25	M4500
Coexpression	DAZARD_RESPONSE_TO_UV_NHEK_DN	GAPVD1 TENT4A PUM2 DIDO1 CHD9 FNBP1L MED13L CEP350 BCAR3 RAPGEF2 PLK4	4.04e-06	300	168	11	M8702
Coexpression	LAKE_ADULT_KIDNEY_C3_PROXIMAL_TUBULE_EPITHELIAL_CELLS_S1_S2	TNRC6B CHD9 ERRFI1 ANKRD11 SIK2 ULK4 PLG SDK1 L3MBTL4	1.36e-05	221	168	9	M39222
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_12HR_UP	KCTD12 TRIM2 CEACAM7 CEACAM1 ERRFI1 ARC CDH1	1.93e-05	128	168	7	MM1000
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ERBB2 CECR2 SLC34A2 MYO1B ITGA9 ERRFI1 CDH1 MYRF ALPI	3.25e-08	181	169	9	b45b11428d13950369347e051d4d517efb2bd4fd
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA ERBB2 CECR2 SLC34A2 CXCL16 ITGA9 ERRFI1 CDH1 MYRF	3.57e-08	183	169	9	ff6dde877659cde9daa3263db0932c9c9ef1adac
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA ERBB2 CECR2 SLC34A2 CXCL16 ITGA9 ERRFI1 CDH1 MYRF	3.92e-08	185	169	9	c82eab551f65ecebe6db908eda9f9eb3414693c7
ToppCell	Bronchial-10x5prime-Epithelial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA TRIM2 NEBL SLC34A2 MYO1B PGC PAX9 CDH1 SLC6A14	7.65e-08	200	169	9	d3ee5f79513e2ac02ad3329b59e6290d457c44d2
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	NAPSA ERBB2 SLC34A2 CXCL16 ITGA9 NEDD9 ERRFI1 ARC CDH1	7.65e-08	200	169	9	ddfb1f006365bf16203ee49f20200f68220cc288
ToppCell	Parenchymal-10x5prime-Epithelial\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA NEBL AZGP1 SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	7.65e-08	200	169	9	4e5b6cb014d9bcb58e13c7511c86c43e27c496e4
ToppCell	PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1-AT1_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANO1 CXCL16 GRM4 CPED1 CDH1 MYRF SLC6A14 TP53BP2	4.92e-07	182	169	8	573771130247e869e4e58f22d4a1cb31989635cf
ToppCell	PND14-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT1\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	ANO1 CXCL16 GRM4 CPED1 CDH1 MYRF SLC6A14 TP53BP2	4.92e-07	182	169	8	6cfaa2b3b3974c13b01c943f4adb70768dcc35e4
ToppCell	COVID-19-Epithelial_cells-ECM-high_epithelial\|COVID-19 / group, cell type (main and fine annotations)	NAPSA FLNB NEBL ZPLD1 SLC34A2 ERRFI1 CDH1 SLC6A14	5.13e-07	183	169	8	dc1d380bf7564f290256cb7108063d1bd2da732b
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA CECR2 SLC34A2 CXCL16 ITGA9 ERRFI1 CDH1 MYRF	5.35e-07	184	169	8	7cc5796557379c3d1db078c1aeda40659c6e401c
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-AT1-AT2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA ERBB2 SLC34A2 CXCL16 ITGA9 ERRFI1 CDH1 MYRF	5.57e-07	185	169	8	3bef59cc0aa939d2a7e52f0f6c61bc00528fe50b
ToppCell	renal_cortex_nuclei-Adult_normal_reference\|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	ESPN FNBP1L NEDD9 PPP2R3A ERRFI1 SIK2 PLG KDM4B	6.55e-07	189	169	8	a48df46274d51e84ffb40264646de7346104efb9
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHD9 MYO1B CEACAM1 CEP350 ANKRD11 PKN2 R3HDM1 CDH1	7.09e-07	191	169	8	60c986d2dcbc19d9338c03da6cb5e1d92fd48f8e
ToppCell	IPF-Epithelial-Club\|World / Disease state, Lineage and Cell class	NAPSA TRIM2 NEBL SLC34A2 FNBP1L ITGA9 CDH1 SDK1	7.09e-07	191	169	8	3c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954
ToppCell	Children_(3_yrs)-Epithelial\|Children_(3_yrs) / Lineage, Cell type, age group and donor	NAPSA NEBL CECR2 SLC34A2 MYO1B FNBP1L CDH1 L3MBTL4	7.09e-07	191	169	8	e432c6e1ae82dddf84314ce73d2b7a991630d905
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL-30m-Epithelial\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHD9 MYO1B CEACAM1 CEP350 ANKRD11 PKN2 R3HDM1 CDH1	7.09e-07	191	169	8	09db184cb90fe282a14474d7217068c58092c6f8
ToppCell	droplet-Large_Intestine-COLON_PROXIMAL-30m\|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CHD9 MYO1B CEACAM1 CEP350 ANKRD11 PKN2 R3HDM1 CDH1	7.09e-07	191	169	8	973117730d6ba5f127e7a0bfabfd0ff2ca7ac131
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	TNRC6B MED13L FAF1 ATXN1 ANKRD11 RAPGEF2 SDK1 L3MBTL4	7.38e-07	192	169	8	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 NEBL MED13L FAF1 ATXN1 RAPGEF2 SDK1 L3MBTL4	8.62e-07	196	169	8	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	LPS_anti-TNF-Epithelial_alveolar-AT_1-2_Progenitor-Progenitor_AT1-AT2\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	NAPSA ERBB2 SLC34A2 CXCL16 NEDD9 ERRFI1 ARC CDH1	9.30e-07	198	169	8	50852713c017217c79777c95857097103bcf2fbe
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 NEBL MED13L FAF1 ATXN1 RAPGEF2 SDK1 L3MBTL4	9.30e-07	198	169	8	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Bronchial-NucSeq-Epithelial-Epi_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NEBL CECR2 SLC34A2 MYO1B FNBP1L SHROOM4 CDH1 L3MBTL4	9.66e-07	199	169	8	725610310e5c5fd7120c0be9acb55bf152026ddd
ToppCell	LPS_IL1RA_TNF-Epithelial_alveolar-AT_1\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	NAPSA ERBB2 SLC34A2 CXCL16 NEDD9 ERRFI1 ARC CDH1	9.66e-07	199	169	8	1c70e7d6bd25980e1b92aa1cac3f3c95d9651b4b
ToppCell	ASK428-Epithelial\|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq	NAPSA NEBL AZGP1 SLC34A2 PGC NEDD9 ERRFI1 SLC6A14	9.66e-07	199	169	8	ba2aaaeb4d9b448a6b9660b152fcac1a0e3fcfe7
ToppCell	Bronchial-10x5prime-Epithelial-Epi_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA NEBL AZGP1 SLC34A2 MYO1B PGC CDH1 SLC6A14	9.66e-07	199	169	8	a38a981cffa61c8444a980916de7414e689a1b63
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	NCOA2 USP25 TNRC6B MED13L FAF1 PACS1 ATXN1 RAPGEF2	9.66e-07	199	169	8	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	LPS_only-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS_only / Treatment groups by lineage, cell group, cell type	NAPSA ERBB2 CECR2 SLC34A2 NEDD9 ERRFI1 CDH1 MYRF	1.00e-06	200	169	8	2dadf317a42a7e27cc1fac74f91b806c93a57108
ToppCell	Parenchymal-10x5prime-Epithelial-Epi_alveolar-AT2\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA AZGP1 SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.00e-06	200	169	8	23088edc62bf7d4db890937bfd7925dc316fcc76
ToppCell	Biopsy_Other_PF-Epithelial\|Biopsy_Other_PF / Sample group, Lineage and Cell type	NAPSA ERBB2 NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	1.00e-06	200	169	8	1ef4d5ae698fa721e0f510bf0d918bd8d3b00591
ToppCell	Parenchymal-10x5prime-Epithelial-Epi_alveolar\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA AZGP1 SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.00e-06	200	169	8	b2d61bc3afac0d78aa30082760da5b1a15d1fad2
ToppCell	Bronchial-10x5prime-Epithelial-Epi_alveolar-AT2\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA AZGP1 SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.00e-06	200	169	8	b535323e18d9fb0dde1e0026df142c831e48c29f
ToppCell	LPS_only-Epithelial_alveolar-AT_1\|LPS_only / Treatment groups by lineage, cell group, cell type	NAPSA ERBB2 SLC34A2 CXCL16 NEDD9 ERRFI1 ARC CDH1	1.00e-06	200	169	8	9a6ae40f3e17cd44ee5fd73260713b920aa2ea15
ToppCell	390C-Epithelial_cells-Epithelial-A_(AT2)\|390C / Donor, Lineage, Cell class and subclass (all cells)	NAPSA AZGP1 SLC34A2 MYO1B PGC BSN SLC6A14	2.68e-06	160	169	7	731def6d82814ebac1a400bc7aea5f6da43ec960
ToppCell	390C-Epithelial_cells-Epithelial-A_(AT2)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	NAPSA AZGP1 SLC34A2 MYO1B PGC BSN SLC6A14	2.68e-06	160	169	7	cf27b4ac4d0caa6f9b068dc8ea93472470a01a4d
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ESPN SYT6 ERRFI1 PLG PC CDH9 L3MBTL4	4.16e-06	171	169	7	f5014e3c387fe3118944af392abe10d6b9b0abab
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NAPSA ADAMTS1 ZPLD1 SLC34A2 ARNT2 SDK1 CDH9	4.32e-06	172	169	7	0c2d0bb767e5ce089b42ad49e8b303a103de2d5c
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	NAPSA ADAMTS1 ZPLD1 SLC34A2 ARNT2 SDK1 CDH9	4.32e-06	172	169	7	eeed177a03c116e9815a8e086d24efc9643b16a4
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ESPN SYT6 ERRFI1 PLG SLC23A1 CDH9 L3MBTL4	4.49e-06	173	169	7	8888434641ea554a9b62c436e87920378eef29cd
ToppCell	COVID-19-Epithelial_cells-AT1\|COVID-19 / group, cell type (main and fine annotations)	NAPSA NEBL SLC34A2 MYO1B FNBP1L CDH1 MYRF	5.62e-06	179	169	7	a0b33bd69ffdfd5d38d80207fb40058a490aa19e
ToppCell	TCGA-Adrenal-Primary_Tumor-Pheochromocytoma-Pheochromocytoma-1\|TCGA-Adrenal / Sample_Type by Project: Shred V9	TRIM2 NEBL PCDHAC2 ARC HTATSF1 IGSF1 ALK	5.62e-06	179	169	7	431e1b29015ec817f778499106d24b19cfc825ae
ToppCell	Control-Epithelial_alveolar-AT_1-AT1-AT2\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA CECR2 SLC34A2 CXCL16 ERRFI1 CDH1 MYRF	6.27e-06	182	169	7	a95956ce4adccb34cc0c47ebfa1878ce4617904e
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Principal_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MYH10 MXRA5 MYO1B ADAMTS16 ULK4 CDH1 SDK1	6.27e-06	182	169	7	f96095b81188b52db8fcfca4837129cfcd9bd7b7
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ESPN RTTN ERRFI1 PLG PC CDH9 L3MBTL4	6.50e-06	183	169	7	facd6dbe0851b537d70a899ac7485714ab27d071
ToppCell	COPD-Epithelial-ATII\|World / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	6.50e-06	183	169	7	8e9aab4eeec2e282c2cab9bfca6dbf40d660c7b9
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NEBL MYO1B FNBP1L NEDD9 ZFYVE9 CDH1 MYRF	6.73e-06	184	169	7	57c792e6e2fedba25d3350ffe649fd74750b579d
ToppCell	LPS-IL1RA-Epithelial_alveolar-AT_1\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA CECR2 SLC34A2 CXCL16 ERRFI1 CDH1 MYRF	6.73e-06	184	169	7	cdf6f1c6cce97a7effa0c55959652e2c0b6992b3
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NEBL MYO1B FNBP1L NEDD9 ZFYVE9 CDH1 MYRF	6.73e-06	184	169	7	d7bd0f0c607bade67c99e9fb3578a570298bf926
ToppCell	COVID-19-Epithelial_cells-Airway_club\|COVID-19 / group, cell type (main and fine annotations)	ERBB2 TRIM2 SLC34A2 FNBP1L ITGA9 CDH1 SDK1	6.97e-06	185	169	7	cfe6fd73d817e173fe803bc1683c291d9bcb8608
ToppCell	Control-Epithelial_alveolar\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA CECR2 SLC34A2 ITGA9 ERRFI1 CDH1 MYRF	6.97e-06	185	169	7	3937e026add96a396122139daf8011cfbc60e75c
ToppCell	IPF-Epithelial-ATII\|World / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	7.22e-06	186	169	7	6a4ff2da0af0f5e590d9f9daa5b5e9ac8c868947
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ESPN ARPP21 AZGP1 PLG PC CDH9 L3MBTL4	7.22e-06	186	169	7	a417e1e21313a7e05951038cdef5ac672a9f727c
ToppCell	10x3'2.3-week_17-19-Endothelial-stroma-proliferating_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	MYH10 MXRA5 FKBP9 MYO1B SHROOM4 ZBTB46 PRCP	7.22e-06	186	169	7	a844d4f79e0ad5d6c60a4488ffd8f4f21b7eed04
ToppCell	Control-Epithelial-ATII\|World / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	7.22e-06	186	169	7	f4b6e401e19a71beddc73d8a1e08359f7c4025cf
ToppCell	LPS_only-Epithelial_alveolar-AT_1\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA SLC34A2 CXCL16 ITGA9 ERRFI1 CDH1 MYRF	7.48e-06	187	169	7	ff26a533d310126521efe1d05cf8b9d32e524550
ToppCell	10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8\|GI_small-bowel / Manually curated celltypes from each tissue	USP9X TNRC6B MED13L PRDM2 ANKRD11 RAPGEF2 TP53BP2	7.75e-06	188	169	7	ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	NAPSA CECR2 SLC34A2 CXCL16 ITGA9 ERRFI1 CDH1	7.75e-06	188	169	7	43a0508d2524a5b310e89e9422843dcaab999bc3
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYH10 ADAMTS1 SPEG ANO1 ADAMTS5 ITGA9 CPED1	7.75e-06	188	169	7	293f2fa99f5f96aa7fd2b2a5cc94ff60eeaabe11
ToppCell	COPD-Epithelial-ATII\|COPD / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	7.75e-06	188	169	7	eb6d79d733b53f64ca615bb777c64ed456866549
ToppCell	IPF-Epithelial-Club\|IPF / Disease state, Lineage and Cell class	NAPSA TRIM2 NEBL SLC34A2 ITGA9 CDH1 SDK1	8.02e-06	189	169	7	f3fcef008ef252b29ac6d567fef27f9acf9cd70f
ToppCell	Control-Epithelial-ATII\|Control / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	8.30e-06	190	169	7	d50902a3abcc18aafa36d83cc2c6e07d7f7cb197
ToppCell	Mesenchymal-airway_smooth_muscle_cell\|World / Lineage, Cell type, age group and donor	MYH10 ADAMTS1 SPEG ANO1 ADAMTS5 ITGA9 TYRP1	8.30e-06	190	169	7	645e56b02edc3702c7db917b8ecd5eed0decaf71
ToppCell	Control-Multiplet-Multiplet\|World / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	8.89e-06	192	169	7	1bfd022d5b87cf8a5d5069f559339a553a52a0a2
ToppCell	Epithelial\|World / Lineage, Cell type, age group and donor	NAPSA NEBL CECR2 SLC34A2 MYO1B FNBP1L CDH1	8.89e-06	192	169	7	499e8893afea5e6d3371e0bd018f7e86a524d669
ToppCell	COPD-Epithelial\|COPD / Disease state, Lineage and Cell class	NAPSA TRIM2 NEBL SLC34A2 MYO1B CFAP299 CDH1	8.89e-06	192	169	7	0644fad5df18f0021f6f49cca996d8cf47f972ff
ToppCell	Control-Epithelial-Club\|Control / Disease state, Lineage and Cell class	TRIM2 NEBL SLC34A2 MYO1B FNBP1L ITGA9 CDH1	8.89e-06	192	169	7	d84ed1ea4a03edaa18c804f75afb03bd7b1f0e16
ToppCell	human_hepatoblastoma-Tumor_cells-T8\|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells)	AZGP1 MYO1B KLC4 PGC ERRFI1 PLG L3MBTL4	8.89e-06	192	169	7	e785135262f4c9cc66c403bf362bb34643b212c5
ToppCell	COPD-Epithelial-Goblet\|COPD / Disease state, Lineage and Cell class	TRIM2 NEBL AZGP1 PAX9 CDH1 SDK1 SLC6A14	8.89e-06	192	169	7	93b2ca0a97776d28c7e8f1a0642c4b63a5554aab
ToppCell	PND03-Epithelial\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NAPSA ANO1 SLC34A2 ERRFI1 CDH1 SLC6A14 TP53BP2	8.89e-06	192	169	7	d8c23693f690d4d568585537bbfedda05d505b3d
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NCOA2 FBXO11 MED13L FAF1 ATXN1 ANKRD11 SIK2	9.19e-06	193	169	7	779276e775cb2492e8dd36436295a536084a6415
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_myocytic\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	ADAMTS1 SPEG ANO1 ADAMTS5 CPED1 TYRP1 IGSF1	9.19e-06	193	169	7	000b9e6a819b94ea2e6e9173daf97ba9ac2b6cc6
ToppCell	Control-Multiplet\|Control / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	9.83e-06	195	169	7	618900c80bea09d46dad3f741bd1bff8bf0a64ee
ToppCell	normal_Lung-Epithelial_cells\|normal_Lung / Location, Cell class and cell subclass	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	9.83e-06	195	169	7	7c90d887afde5c4d63352b5171be9987e2dfca58
ToppCell	Control-Multiplet-Multiplet\|Control / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	9.83e-06	195	169	7	06ac685855e14e4dd2cbe6d0e73f894f2eeff91f
ToppCell	Control-Epithelial\|Control / Disease state, Lineage and Cell class	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	9.83e-06	195	169	7	1798c3b89b1b5ff4f5777d2b9f52dc81cdad28fa
ToppCell	NS-moderate-d_16-33-Epithelial-Secretory\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	FLNB ERBB2 FAM114A1 MYO1B SYNGR1 CDH1 SLC6A14	1.02e-05	196	169	7	70384c1da9baed843f414cfd1403ddd586a2db07
ToppCell	tumor_Lymph_Node_/_Brain\|World / Location, Cell class and cell subclass	ESPN NAPSA TRIM2 AZGP1 SLC34A2 PDXK CDH1	1.02e-05	196	169	7	b39f938cbef54f08c53035738b97c76e7295733a
ToppCell	11.5-Distal-Mesenchymal-Airway_Smooth_Muscle\|Distal / Age, Tissue, Lineage and Cell class	SPEG ANO1 ADAMTS5 ITGA9 CPED1 TYRP1 IGSF1	1.02e-05	196	169	7	05530fe7a5681c2f39b95016cd22ef99d6ac0430
ToppCell	15-Distal-Mesenchymal-Airway_Smooth_Muscle\|Distal / Age, Tissue, Lineage and Cell class	SPEG ANO1 ADAMTS5 ITGA9 CPED1 TYRP1 IGSF1	1.02e-05	196	169	7	0e45817625b96d21a8cc4dfbbd465ee6403b6802
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_2-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CECR2 SLC34A2 ITGA9 ERRFI1 CDH1 MYRF	1.04e-05	130	169	6	6434d9106ccb38786dad36fab80163dfc07b6eb7
ToppCell	LPS_IL1RA-Epithelial_alveolar-AT_1-Differentiating_AT2\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	NAPSA SLC34A2 ITGA9 NEDD9 ERRFI1 CAMTA1 CDH1	1.05e-05	197	169	7	b94645d57efe8d9e032bffb8c89af1f425c6421e
ToppCell	LAM-Epithelial\|LAM / Condition, Lineage and Cell class	NAPSA AZGP1 SLC34A2 MYO1B PGC CDH1 SLC6A14	1.05e-05	197	169	7	e5cf07061f6d9db7f12ac17209b267373fa2270b
ToppCell	LPS_only-Epithelial_alveolar-AT_2\|LPS_only / Treatment groups by lineage, cell group, cell type	NAPSA SLC34A2 CXCL16 PGC ERRFI1 CDH1 SEC23B	1.09e-05	198	169	7	d087e738d69ca9853553fde46d4e7a8906439d32
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NAPSA SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.09e-05	198	169	7	691a2f1779225e5519155460eeb6a2aac5f67a92
ToppCell	Bronchial-10x5prime-Epithelial-Epi_alveolar-AT1\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 MYRF	1.09e-05	198	169	7	54228dd9a50616d2022712d162a419ed0327cabd
ToppCell	LPS_only-Epithelial_alveolar-AT_2-AT2\|LPS_only / Treatment groups by lineage, cell group, cell type	NAPSA SLC34A2 CXCL16 PGC ERRFI1 CDH1 SEC23B	1.09e-05	198	169	7	6b6572deeca98ccb015f2aa3c5ce27de44445f74
ToppCell	5'-Adult-LargeIntestine-Epithelial-Tuft-related\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FLNB NEBL AZGP1 CEACAM7 MYO1B CEACAM1 PRKG2	1.09e-05	198	169	7	a631be84e29c277216d89ec6265bd43e87c1dc86
ToppCell	COVID-19-Epithelial-AT2,_AT1_cells\|COVID-19 / Condition, Lineage and Cell class	NAPSA SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.09e-05	198	169	7	7e6f089e71e70190ff8486341ab06719d7741467
ToppCell	distal-mesenchymal-Fibromyocyte-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYH10 ADAMTS1 FAM133A SPEG ANO1 ADAMTS5 TYRP1	1.09e-05	198	169	7	9d1d95e7703cfc70a8ad427e400c340dbd205db8
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	NAPSA SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.09e-05	198	169	7	aed0476248e9637897eefb1623ec4035f2dacd82
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	NAPSA SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.09e-05	198	169	7	e115eea04012e9e492e923ed080e1723c38d14fd
ToppCell	BAL-Severe-Epithelial-Epithelial-AT1/AT2-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	NAPSA SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.09e-05	198	169	7	33d1e0b6f57663544bee0ffdde83a65da764d44c
ToppCell	Severe_COVID-19-Epithelial-AT1/AT2\|Severe_COVID-19 / Disease group,lineage and cell class （2021.01.30）	NAPSA SLC34A2 MYO1B PGC ERRFI1 CDH1 SLC6A14	1.09e-05	198	169	7	43e33d28d9de5033bd00d39be953542a225236ed
ToppCell	distal-mesenchymal-Fibromyocyte\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MYH10 ADAMTS1 FAM133A SPEG ANO1 ADAMTS5 TYRP1	1.09e-05	198	169	7	fbfac1d10e4224990a094cc84b74bbc206881423
ToppCell	Bronchial-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NEBL CECR2 SLC34A2 MYO1B FNBP1L CDH1 L3MBTL4	1.12e-05	199	169	7	5f7da3eab58ace6cddb3179a415cd839d5767958
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA NEBL CECR2 SLC34A2 MYO1B FNBP1L CDH1	1.12e-05	199	169	7	8587bd98de7767a575088afbea07a1feb4516b9b
ToppCell	medial-2-Epithelial-Alveolar_Epithelial_Type_1\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NAPSA NEBL SLC34A2 MYO1B ERRFI1 CDH1 MYRF	1.12e-05	199	169	7	456460c761e26ed4b1d88d9bee4d2a7c9bd9d416
ToppCell	Parenchymal-10x5prime-Epithelial-Epi_alveolar-AT1\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	NAPSA ERBB2 NEBL SLC34A2 MYO1B CDH1 MYRF	1.12e-05	199	169	7	aca81a879ef9c196bd1885eff4c63ffe6c9682b7
ToppCell	LPS_only-Epithelial_alveolar-AT_1-2_Progenitor\|LPS_only / Treatment groups by lineage, cell group, cell type	NAPSA SLC34A2 CXCL16 NEDD9 ERRFI1 ARC CDH1	1.12e-05	199	169	7	3a0af1a13b1760f4213d87d0958dbe3bf3b9a42b
ToppCell	Epithelial_cells\|World / lung cells shred on cell class, cell subclass, sample id	NAPSA NEBL SLC34A2 MYO1B PGC CDH1 SLC6A14	1.12e-05	199	169	7	bbe69e44b7970f57628365ae771790f2b13d0cae
ToppCell	medial-Epithelial-Alveolar_Epithelial_Type_1-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	NAPSA NEBL SLC34A2 MYO1B ERRFI1 CDH1 MYRF	1.12e-05	199	169	7	5263338242f95c04690d0795749ccc20b0d19f7a
Drug	irinotecan HCl; Down 200; 100uM; PC3; HT_HG-U133A	NCOA2 CHD9 FNBP1L MED13L ZFHX4 ATXN1 SEC24B ANKRD11 PKN2 BCAR3 RAPGEF2 KDM4B	5.23e-09	171	167	12	7535_DN
Drug	irinotecan HCl; Down 200; 100uM; MCF7; HT_HG-U133A	NCOA2 BARD1 DIDO1 CHD9 FBXO11 FNBP1L MED13L PRDM2 CEP350 SEC24B RAPGEF2 CDH1	1.12e-08	183	167	12	7498_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; PC3; HT_HG-U133A	PUM2 DIDO1 CHD9 PRDM2 CEP350 NEDD9 SEC24B BCAR3 RAPGEF2 EP300	9.00e-07	180	167	10	4541_DN
Drug	Cefazolin sodium salt [27164-46-1]; Down 200; 8.4uM; PC3; HT_HG-U133A	ERBB2 NEBL MINK1 MYO1B GTF3C5 NEDD9 RIN1 PPP2R3A MYRF EP300	1.86e-06	195	167	10	7385_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	NCOA2 PUM2 CHD9 FBXO11 MED13L PRDM2 CEP350 SEC24B RAPGEF2	8.28e-06	182	167	9	3887_DN
Drug	Camptothecine (S,+) [7689-03-4]; Down 200; 11.4uM; MCF7; HT_HG-U133A	NCOA2 PUM2 CHD9 PRDM2 CEP350 SEC24B RAPGEF2 PLK4 KDM4B	9.04e-06	184	167	9	2321_DN
Drug	Primaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A	MBTPS1 MYH10 CHD9 PRDM2 CEP350 PPP2R3A NUP210 ANKRD11 CDH1	1.07e-05	188	167	9	4845_DN
Drug	pyridoxamine	TFG PGC PDXK PLG PLGLB1 PC PLK4	1.25e-05	105	167	7	CID000001052
Drug	Naproxen [22204-53-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A	NCOA2 NDE1 TNRC6B FBXO11 ADAMTS5 CEP350 PPP2R3A SYNGR1 ARC	1.44e-05	195	167	9	1706_UP
Drug	Clobetasol propionate [25122-46-7]; Down 200; 8.6uM; PC3; HT_HG-U133A	SPEG PROSER1 CUL7 GTF3C5 TNK2 PAX9 PC MYRF PLK4	1.50e-05	196	167	9	4497_DN
Drug	Aminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; HL60; HT_HG-U133A	ARPP21 ADAMTS1 AZGP1 CEACAM7 GRM4 CPED1 SYNGR1 TNK2 KDM4B	1.56e-05	197	167	9	2351_UP
Drug	Sulfameter [651-06-9]; Up 200; 14.2uM; MCF7; HT_HG-U133A	NCOA2 FAM114A1 CEACAM7 IFNAR1 RIN1 ZFYVE9 SYNGR1 SIK2 MAPKBP1	1.56e-05	197	167	9	3453_UP
Drug	AC1MHU3O	PDXK PPP2R3A EP300	2.11e-05	8	167	3	CID003032423
Drug	AC1L1G2K	MBTPS1 ERBB2 ADAMTS1 ADAMTS5 PLG BSN	3.61e-05	84	167	6	CID000003498
Drug	cytochalasin B; Up 200; 20.8uM; MCF7; HT_HG-U133A_EA	FLNB TRIM2 NEBL NEDD9 ATXN1 NUP210 KDM4A BCAR3	4.29e-05	173	167	8	1122_UP
Disease	sexual dimorphism measurement	GAPVD1 C20orf173 GRM4 FAF1 FAM133B PACS1 SMIM23 ZBTB46 CASKIN1 SEC16A ANKRD11 ULK4 AURKAIP1 PRKG2 MAPKBP1 BSN PC MYRF NPAS4 KPNA3	1.87e-06	1106	157	20	EFO_0021796
Disease	age at menopause	NLRP11 NCOA2 TENT4A PIWIL1 DIDO1 FBXO11 ZFHX4 CHD6 KPNA3	3.69e-05	302	157	9	EFO_0004704
Disease	a disintegrin and metalloproteinase with thrombospondin motifs 5 measurement	ADAMTS1 ADAMTS5	8.41e-05	3	157	2	EFO_0008326
Disease	ascending aortic diameter	FLNB ANO1 TNRC6B MED13L ULK4 USP15	1.08e-04	140	157	6	EFO_0021787
Disease	obesity (implicated_via_orthology)	ETV4 PUM2 MED13L ZFHX4 SEC16A DCHS1 SDK1	1.60e-04	215	157	7	DOID:9970 (implicated_via_orthology)
Disease	HIV-1 infection, Susceptibility to viral and mycobacterial infections	NEDD9 PRKG2 PC	1.83e-04	21	157	3	EFO_0000180, Orphanet_391311
Disease	prostate cancer (is_marker_for)	NCOA2 AZGP1 KDM4A CDH1 EP300 KDM4B	1.94e-04	156	157	6	DOID:10283 (is_marker_for)
Disease	Primary microcephaly	NDE1 RTTN PLK4	2.11e-04	22	157	3	C0431350
Disease	stomach carcinoma (is_marker_for)	ERBB2 AZGP1 KDM4A	2.76e-04	24	157	3	DOID:5517 (is_marker_for)
Disease	multiple sclerosis	NLRP11 ESPN NCOA2 TRIM2 TENT4A ZPLD1 MINK1 TSFM IFNAR1 ZBTB46 ATXN1	3.56e-04	594	157	11	MONDO_0005301
Disease	melanoma	MYO1B RIN1 TYRP1 KDM4A ALK EP300 KDM4B	3.81e-04	248	157	7	C0025202
Disease	Carcinoma, Lobular	CDH1 TP53BP2	4.16e-04	6	157	2	C0206692
Disease	reticulocyte measurement	FLNB TRIM2 USP9X FKBP9 TNRC6B MYO1B FAF1 PACS1 USP42 ATXN1 PKN2 BSN CDH1 SLC23A1 KPNA3	5.22e-04	1053	157	15	EFO_0010700
Disease	Mammary Carcinoma, Human	NCOA2 ERBB2 ADAMTS1 BARD1 ETV4 BCAR3 CDH1 ALK EP300 TP53BP2	5.31e-04	525	157	10	C4704874
Disease	Mammary Neoplasms, Human	NCOA2 ERBB2 ADAMTS1 BARD1 ETV4 BCAR3 CDH1 ALK EP300 TP53BP2	5.31e-04	525	157	10	C1257931
Disease	Mammary Neoplasms	NCOA2 ERBB2 ADAMTS1 BARD1 ETV4 BCAR3 CDH1 ALK EP300 TP53BP2	5.47e-04	527	157	10	C1458155
Disease	CHARGE syndrome (implicated_via_orthology)	CHD9 CHD6	5.80e-04	7	157	2	DOID:0050834 (implicated_via_orthology)
Disease	Ovarian neoplasm	ERBB2 CDH1	5.80e-04	7	157	2	cv:C0919267
Disease	invasive lobular carcinoma (is_marker_for)	ERBB2 CDH1	5.80e-04	7	157	2	DOID:3457 (is_marker_for)
Disease	Malignant neoplasm of breast	NCOA2 FLNB ERBB2 ADAMTS1 BARD1 APCS ETV4 ITGA9 G3BP2 BCAR3 MMP10 CDH1 ALK EP300 TP53BP2	6.39e-04	1074	157	15	C0006142
Disease	Breast Carcinoma	NCOA2 ERBB2 ADAMTS1 BARD1 ETV4 BCAR3 CDH1 ALK EP300 TP53BP2	6.41e-04	538	157	10	C0678222
Disease	Tinnitus	ANO1 TNRC6B PRCP USP15 SDK1	6.71e-04	130	157	5	HP_0000360
Disease	sphingomyelin measurement	TENT4A MINK1 CERS5 ANKRD11 PLG MYRF SDK1	7.49e-04	278	157	7	EFO_0010118
Disease	diastolic blood pressure, systolic blood pressure	GAPVD1 SPEG DNAH2 ANO1 TNRC6B FBXO11 CEP350 SLC7A6OS SEC16A ULK4 CHD6	9.59e-04	670	157	11	EFO_0006335, EFO_0006336
Disease	Bipolar Disorder	KCTD12 ITGA9 GRM4 ME2 PACS1 SYNGR1 ULK4 MMP10 PC	1.08e-03	477	157	9	C0005586
Disease	alopecia areata (is_marker_for)	KDM4A KDM4B	1.23e-03	10	157	2	DOID:986 (is_marker_for)
Disease	worry measurement	GAPVD1 ARPP21 PPP2R3A KDM4A CAMTA1	1.43e-03	154	157	5	EFO_0009589
Disease	Mammary Ductal Carcinoma	ERBB2 CDH1	1.50e-03	11	157	2	C0021367
Disease	Invasive Ductal Breast Carcinoma	ERBB2 CDH1	1.50e-03	11	157	2	C1134719
Disease	Non-Small Cell Lung Carcinoma	ERBB2 MXRA5 ADAMTS1 SLC34A2 ALK	1.51e-03	156	157	5	C0007131
Disease	Gastric Adenocarcinoma	SPEG MINK1 TNK2	1.78e-03	45	157	3	C0278701
Disease	Neuroblastoma	BARD1 CHD6 ALK	2.02e-03	47	157	3	C0027819
Disease	illegal drug consumption	SYT6 ITGA9	2.11e-03	13	157	2	EFO_0005431
Disease	aortic measurement	FLNB MYH10 ANO1 TNRC6B ULK4 USP15	2.32e-03	251	157	6	EFO_0020865
Disease	body surface area	TENT4A DIDO1 MED13L PRDM4 CPED1 SMIM23 SYNGR1 ANKRD11 ULK4 PRKG2	2.41e-03	643	157	10	EFO_0022196
Disease	urinary bladder cancer (is_marker_for)	ERBB2 KDM4A CDH1 KDM4B	2.60e-03	107	157	4	DOID:11054 (is_marker_for)
Disease	severe acute respiratory syndrome, COVID-19	NCOA2 MXRA5 USP9X CECR2 NUP210 ARNT2 CAMTA1 SLC23A1	2.80e-03	447	157	8	EFO_0000694, MONDO_0100096
Disease	acute graft vs. host disease, donor genotype effect measurement	CRHBP SDK1	2.82e-03	15	157	2	EFO_0004599, EFO_0007892
Disease	unipolar depression, cognitive function measurement	MYH10 ADAMTS5	2.82e-03	15	157	2	EFO_0003761, EFO_0008354
Disease	osteoarthritis (implicated_via_orthology)	ADAMTS5 ERRFI1	2.82e-03	15	157	2	DOID:8398 (implicated_via_orthology)
Disease	multiple myeloma	NCOA2 DIDO1 ANKRD11 ULK4	3.07e-03	112	157	4	EFO_0001378
Disease	pulse pressure measurement	FLNB MXRA5 NEBL ANO1 TNRC6B MED13L ITGA9 GRM4 FAF1 ZBTB46 ZFHX4 ATXN1 ANKRD11 ULK4 PKN2 KDM4B	3.15e-03	1392	157	16	EFO_0005763
Disease	Diffuse Large B-Cell Lymphoma	FBXO11 ALK EP300	3.17e-03	55	157	3	C0079744
Disease	Alcoholic Intoxication, Chronic	CRHBP ARC ALK CDH9 EP300 KPNA3	3.20e-03	268	157	6	C0001973
Disease	vision disorder	MYH10 SDK1	3.21e-03	16	157	2	MONDO_0021084
Disease	level of Phosphatidylcholine (18:0_20:3) in blood serum	NDE1 MYRF	3.21e-03	16	157	2	OBA_2045093
Disease	ovarian cancer (is_implicated_in)	ERBB2 BARD1 CDH1	3.33e-03	56	157	3	DOID:2394 (is_implicated_in)
Disease	Carcinoma, Granular Cell	ERBB2 AZGP1 CEACAM1 TYRP1	3.48e-03	116	157	4	C0205644
Disease	Adenocarcinoma, Tubular	ERBB2 AZGP1 CEACAM1 TYRP1	3.48e-03	116	157	4	C0205645
Disease	Adenocarcinoma, Oxyphilic	ERBB2 AZGP1 CEACAM1 TYRP1	3.48e-03	116	157	4	C0205642
Disease	Carcinoma, Cribriform	ERBB2 AZGP1 CEACAM1 TYRP1	3.48e-03	116	157	4	C0205643
Disease	Adenocarcinoma, Basal Cell	ERBB2 AZGP1 CEACAM1 TYRP1	3.48e-03	116	157	4	C0205641
Disease	Adenocarcinoma	ERBB2 AZGP1 CEACAM1 TYRP1	3.48e-03	116	157	4	C0001418
Disease	Benign neoplasm of stomach	ERBB2 CDH1	3.63e-03	17	157	2	C0153943
Disease	Neoplasm of uncertain or unknown behavior of stomach	ERBB2 CDH1	3.63e-03	17	157	2	C0496905
Disease	Carcinoma in situ of stomach	ERBB2 CDH1	3.63e-03	17	157	2	C0154060
Disease	phosphatidylcholine 40:6 measurement	RAPGEF2 MYRF	3.63e-03	17	157	2	EFO_0010389
Disease	S-6-hydroxywarfarin measurement	NEBL AZGP1 MINK1 CHD9 NEDD9 DCHS1 PLG	3.66e-03	368	157	7	EFO_0803326
Disease	cutaneous melanoma	MED13L TYRP1 ANKRD11 CDH1	4.05e-03	121	157	4	EFO_0000389
Disease	Hereditary Non-Polyposis Colon Cancer Type 2	BARD1 CDH1	4.53e-03	19	157	2	C1333991
Disease	Colorectal cancer, hereditary nonpolyposis, type 1	BARD1 CDH1	4.53e-03	19	157	2	C2936783
Disease	age at first sexual intercourse measurement	ARPP21 SPEG ZBTB46 IGSF1 CAMTA1 SDK1 KDM4B	4.55e-03	383	157	7	EFO_0009749
Disease	cognitive decline measurement	NEBL MED13L CFAP299 ARC CHD6 PLG R3HDM1 SDK1	4.63e-03	486	157	8	EFO_0007710
Disease	oral squamous cell carcinoma (is_marker_for)	ERBB2 AZGP1 CDH1	4.65e-03	63	157	3	DOID:0050866 (is_marker_for)
Disease	age at menarche	DNAH2 PRDM2 ZBTB46 ZFHX4 CRTAM KDM4A IGSF1 BSN KDM4B	4.66e-03	594	157	9	EFO_0004703
Disease	fish consumption measurement	ATXN1 SIK2 SDK1	4.86e-03	64	157	3	EFO_0010139
Disease	cholesteryl esters to total lipids in medium VLDL percentage	TENT4A PLG MYRF	4.86e-03	64	157	3	EFO_0022253

Protein segments in the cluster

Peptide	Gene	Start	Entry
SGQGEPLDDYVNTQG	PLGLB1	16	Q02325
AFGGAVENPEYLTPQ	ERBB2	1186	P04626
VENPEYLTPQGGAAP	ERBB2	1191	P04626
PYTQNPGQQIGASGL	EP300	256	Q09472
VQGLYPVAQPSLGNA	CAMTA1	741	Q9Y6Y1
YGGNPQQSNRKGETP	ANKRD11	256	Q6UB99
IPSVEYLLQNGSDPN	BARD1	441	Q99728
QEYVQLQGDPFGLPS	CTF1	46	Q16619
PTGHGTQEQEVYQVP	NEDD9	121	Q14511
YDVANPVGNPGSVLT	CPED1	486	A4D0V7
KQNEAPGPRNSGVNY	BCAR3	461	O75815
LGPEELPGQTYDATQ	ADAMTS5	481	Q9UNA0
GELPGQEPAEAQQYQ	ARC	181	Q7LC44
NPVTFNENGDAPGRY	GRM4	461	Q14833
VYLTQPGNGNEGSVT	CXCL16	21	Q9H2A7
GYVKNISQENAPGPA	CEACAM7	81	Q14002
YTGPGDQTVNPQNGF	DDX20	616	Q9UHI6
GTQPPVIGYLSGQQQ	ATXN1	456	P54253
IGIEDSGPYQAQPNA	CERS5	76	Q8N5B7
GATQPNGLSQEGPIY	CECR2	1396	Q9BXF3
LTPQTNGQPGSDTLY	CELF6	321	Q96J87
ENIYSNSQGKPGSPE	TP53BP2	661	Q13625
PQAAQQAGYQPVLSG	ARPP21	671	Q9UBL0
SYNEPENLIATGPTN	ADAMTS16	821	Q8TE57
AGPSQGQTNYAFVPE	TNK2	661	Q07912
PGDPTQGTGNYNIED	ARNT2	691	Q9HBZ2
DPLYEQAGQPAVDQG	ETV4	231	P43268
IPPGQQNNLSSSVGY	R3HDM1	776	Q15032
PGAAPGIYQQSAEAS	RBM10	501	P98175
IQLPGDLPGTSYDAN	ADAMTS1	471	Q9UHI8
GLESLQFDYPGNQVP	PUM2	231	Q8TB72
GVQAEQQSPGPAAYT	ODF3B	131	A8MYP8
IYEGQLGPDNPNVAR	KLC4	366	Q9NSK0
SQDDVNGIQSLYGPP	MMP10	251	P09238
YELQLQNSIPGPEGD	NUP210	281	Q8TEM1
QVQAQAPDGGPITYH	DCHS1	1021	Q96JQ0
SYQLLVQVQDGGSPP	DCHS1	1176	Q96JQ0
SQPPVAHAGQVYGEQ	CASKIN1	446	Q8WXD9
QEAKYGQAPNGLPAV	PAX9	251	P55771
LIPEATQGGTYNFDP	KPNA3	496	O00505
GPTQSVGPTIQDYLN	FAM133A	21	Q8N9E0
QAPPSYGQLIAQGAI	LRP10	491	Q7Z4F1
DGYNNVPSVGSLADP	MED13L	996	Q71F56
IGNDGPLYGTLNNPA	MBTPS1	336	Q14703
PYLPQNGDNIEVAFS	MBTPS1	536	Q14703
ASQPGSIIPNSNLDY	NLRP11	996	P59045
YPEGVNAQTKNGATP	ESPN	161	B1AK53
NPEQYGIISDAPINE	GAPVD1	321	Q14C86
VNYSALPENENVGPG	BEND2	276	Q8NDZ0
EYGQAAQPAAEGTPA	BSN	1236	Q9UPA5
ANYGSQTEDLPQAPS	BSN	1426	Q9UPA5
TGGENPNSLAIYQLP	DCAF12L2	166	Q5VW00
EVGQALYGAPSQAPL	CCDC120	596	Q96HB5
DPSITLGQYVQPQGV	TSFM	291	P43897
GEPGQAGNPALVSAY	FLNB	2376	O75369
GAPKQSGNTPVIQDY	IFNAR1	351	P17181
TGTGNVNIIQPNYPA	MTG1	286	Q9BT17
PQTYLQAEGEDGQNL	CUL7	1546	Q14999
PGAENQPVIAIGGSY	PRCP	166	P42785
TFNPPIYGADVNGTL	KDM4A	126	O75164
GGENTEPLPANSYIG	KDM4B	736	O94953
PDGPGVQNTDFLLYV	LMLN2	176	A0A1B0GTW7
QENGRTLIAPQGYPN	L3MBTL4	251	Q8NA19
GTAPNDPLDLGYEVQ	ANO1	846	Q5XXA6
SAEGDYPQQAFTGIP	PPP2R3A	81	Q06190
YELLTGNPPFSGVDQ	PRKG2	641	Q13237
GGYSSINNVQDPQKP	MAN1B1	636	Q9UKM7
SPNSPYGDVIGLQVD	PACS1	811	Q6VY07
NGEQTQNREPESPYG	TENT4A	556	Q5XG87
YTPNPVGTENEDLSN	PROSER1	236	Q86XN7
GEPDSLGQQPTDTPY	HTATSF1	36	O43719
PDVNESESGSPDYQQ	ALPI	426	P09923
YSVPEEQAPGALVGN	PCDHAC2	46	Q9Y5I4
AYGNEGVSGVIPPNS	FKBP9	116	O95302
VVAGIPAGAYNLDPQ	ITGA9	21	Q13797
EGPEGPITANNYPIS	NPAS4	301	Q8IUM7
TGINPALSYTQPQGI	CHD9	2466	Q3L8U1
EGAQEPLEQQRPSGY	IGSF1	1101	Q8N6C5
YTDDANQEVRGPPQQ	FNBP1L	506	Q5T0N5
GPIQSSGPTIQDYLN	FAM133B	21	Q5BKY9
QDPDLTTEANPQYLG	CRTAM	266	O95727
LEPYELENPNGNSIG	CRHBP	301	P24387
GQNVFPTYPLEGSEL	CHD6	2006	Q8TD26
GYAIGTQQATPGPAN	CEACAM1	81	P13688
YNALPQENGLSPGAI	CEACAM1	416	P13688
VAEESGPGAQNSPYQ	FBXO11	86	Q86XK2
SSLEYGTEPSPGQAQ	C1orf226	146	A1L170
QPSPEPVQENANSGY	G3BP2	161	Q9UN86
PGAIRANGEVNPQYD	GALT	76	P07902
YTSQGVPINGGLPQN	HYAL4	101	Q2M3T9
QETQAKPGYQPSGES	CEP350	681	Q5VT06
QDAPYNEVTGAPAQF	DIDO1	1856	Q9BTC0
TPGQGNNVYIFPGVA	ME2	461	P23368
GPYGLQEGSPQTPDQ	MAPKBP1	1051	O60336
TGGENPNSLAIYQLP	DCAF12L1	166	Q5VU92
PQENGILQSEYGGET	FAF1	46	Q9UNN5
GQQALPGVSFQPESE	C1orf127	86	Q8N9H9
QIPQGSSLGNDIDQY	C20orf173	91	Q96LM9
TPENGVNPADGENYV	DNAH2	2296	Q9P225
QNDSPGDASEGPEYL	RUBCN	311	Q92622
LQPGYQNATAPLISG	SEC24B	466	O95487
AGLPGEYQQRNITSP	SDK1	811	Q7Z5N4
PLPDSQYNGNPESVG	SDK1	1196	Q7Z5N4
YGPELQANITAGPAE	SDK1	1886	Q7Z5N4
VNEAGYGEPSNPSTA	SDK1	1981	Q7Z5N4
ILQGQPYFSVDPESG	CDH9	201	Q9ULB4
YSEPEQQEGASAGAP	KCTD12	161	Q96CX2
SNGYIPIPGQQDKDN	MYH10	311	P35580
NPTTYKGQVPENEAN	CDH1	376	P12830
YNGIDLPVENPADGT	PRDM2	896	Q13029
ALDPYQSNGNVGLEP	PRDM4	146	Q9UKN5
QEQNYLAVDSPPSGG	FAM114A1	111	Q8IWE2
YEAQVPENNPLGSLV	PCDHB6	246	Q9Y5E3
ADSNGYTNLPDVVQP	MINK1	901	Q8N4C8
IYLQPPSGNSQDQGK	OR2J3	261	O76001
LVGSTASQQPGYIQP	PIWIL1	21	Q96J94
PILQGYADTEDPLGN	RTTN	721	Q86VV8
SSVDYGNELPPAAEQ	SYT6	186	Q5T7P8
AQENYEGSEEVSPPQ	USP9X	2536	Q93008
AQDPLYDVPNASGGQ	RIN1	31	Q13671
LAVPQGLEYQTNEPS	SMIM23	71	A6NLE4
QYPVDGAQQSDLTGP	SIK2	866	Q9H0K1
GSFQYVPVQLQGGAP	SHROOM4	6	Q9ULL8
GQSNIAPQPVGYAAG	PRRC1	291	Q96M27
PDTPQSGLEYSGIQE	PKN2	626	Q16513
SGQGEPLDDYVNTQG	PLG	16	P00747
PNGQTTRYGENEKLP	PLK4	931	O00444
DLSYVSDQNGGVPDP	ERRFI1	221	Q9UJM3
PSPQGSNYLIVLGSQ	PDXK	191	O00764
RNQFPPAYGGISEVN	SEC23B	91	Q15437
PAYGGISEVNQPAEL	SEC23B	96	Q15437
GQNSGNYFAPIPLED	EIF4ENIF1	376	Q9NRA8
YQQQGLPLEAATAPG	ALK	1586	Q9UM73
SGLLSGQAQENPGYP	ARNTL	551	O00327
YQCPPSQIGEGAEQG	AURKAIP1	101	Q9NWT8
NSSPNYQVIADNPEG	CFAP299	171	Q6V702
SQANPAYQAPSDING	NCOA2	1341	Q15596
QPNPDKYLEGAAGQQ	SLC34A2	11	O95436
TISYPSGIPDGQLQA	UFSP2	211	Q9NUQ7
DGLQYSPVQGGDPSE	PIAS3	426	Q9Y6X2
SSGQESEYTPGNPEA	SLC7A6OS	116	Q96CW6
PQKPYNDIGIGQSQD	RAPGEF2	546	Q9Y4G8
YQNQPGSSEAVSPGD	USP42	16	Q9H9J4
VENLNAPPAEAGYDQ	ZFHX4	2736	Q86UP3
GPDGNTPQFENISIY	TYRP1	171	P17643
QVGNISGYIDTPDPP	ZPLD1	126	Q8TCW7
GNSESPGKPEINSVY	ZSCAN5DP	316	P0CG00
AAYFGEISIGTPPQN	PGC	71	P20142
GVEPTYLSSQNGQPL	PGC	346	P20142
GPGAPNLDRFYQQVT	SEC16A	1031	O15027
DFGNAQELTPGEPQY	SPEG	1741	Q15772
LPNYLESNPGAINTG	SLC23A1	471	Q9UHI7
ENILSAYQGTPLPAN	APCS	186	P02743
QPPYTGAQTQAGQIE	TFG	226	Q92734
QYPAGTQGEQLEVPE	SPSB2	151	Q99619
TAQAAGDPEYLEQPS	USP25	731	Q9UHP3
GDQNVYPGPIDNSGL	USP15	56	Q9Y4E8
GGTYQQPANTFDTEP	SYNGR1	211	O43759
PEAGQYGPVAGTLNA	TEX13C	166	A0A0J9YWL9
GPAVPQENQDGRYSL	AZGP1	16	P25311
QNTYPAGGNPRSLEN	ZNF496	331	Q96IT1
GYSGANQDAVLDVPP	ZNF648	151	Q5T619
REGYNNPPISGENLI	GTF3C5	191	Q9Y5Q8
DQPAVPGETQGDSYF	WDR3	731	Q9UNX4
INTSADPLYGPQGLA	TRIM2	706	Q9C040
INGSEIYQPGQLPSE	SLC6A14	201	Q9UN76
GTDPNIPDEYGNTAL	POTEH	266	Q6S545
SGNSDVYENEIPGGQ	PC	856	P11498
QAGLYVTESPQPQEA	WDR81	1086	Q562E7
DQVGYQAGSNGQPLP	ZFYVE9	1371	O95405
EQVSPSQYGGSELPS	ZBTB46	231	Q86UZ6
GSPYNQFDIIPGDTL	TNRC6B	1431	Q9UPQ9
AGITDQGEVPNGYNV	TRBV6-5	71	A0A0K0K1A5
LYGGENPDSLSPENV	ULK4	1186	Q96C45
PDPSQYQSLGEDTQA	TSPYL5	36	Q86VY4
PSSVGQPFQGAYLEI	MYO1B	956	O43795
NVTGEQGGPDVVQPY	NAALADL1	136	Q9UQQ1
LNYVGNPETEATPVN	MXRA5	1531	Q9NR99
VQYFGEIGLGTPPQN	NAPSA	76	O96009
VANANGPEGPNYRSE	MYOZ3	91	Q8TDC0
DSGSEAYSPQQVNEP	MYRF	141	Q9Y2G1
NLVYDQSPNRTGGPA	NDE1	276	Q9NXR1
PSDEGAPVLPGAYQQ	NEBL	916	O76041